

Kadoaki Ohashi

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/4875656/kadoaki-ohashi-publications-by-year.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

105 papers	3,586 citations	20 h-index	59 g-index
132 ext. papers	4,391 ext. citations	5.4 avg, IF	4.66 L-index

#	Paper	IF	Citations
105	Identification of targetable kinases in idiopathic pulmonary fibrosis.. <i>Respiratory Research</i> , 2022 , 23, 20	7.3	0
104	Deciphering the clinical features of heterogeneous stage III non-small cell lung cancer in Japanese real-world clinical practice: Expanded cohort of the SOLUTION study.. <i>Lung Cancer</i> , 2021 , 165, 152-163	5.9	1
103	Comparison of bronchoscopy and computed tomography-guided needle biopsy for re-biopsy in non-small cell lung cancer patients. <i>Respiratory Investigation</i> , 2021 , 59, 240-246	3.4	0
102	VEGFR2 blockade augments the effects of tyrosine kinase inhibitors by inhibiting angiogenesis and oncogenic signaling in oncogene-driven non-small-cell lung cancers. <i>Cancer Science</i> , 2021 , 112, 1853-1864	6.9	5
101	A novel osimertinib-resistant human lung adenocarcinoma cell line harbouring mutant EGFR and activated IGF1R. <i>Japanese Journal of Clinical Oncology</i> , 2021 , 51, 956-965	2.8	2
100	Phase II study of brigatinib in ROS1 positive non-small cell lung cancer (NSCLC) patients previously treated with crizotinib: Barossa cohort 2.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 9040-9040	2.2	
99	Impact on second-line treatment after failure of immune checkpoint inhibitor (ICI) combination chemotherapy in extensive-disease small cell lung cancer: Experience of the Okayama Lung Cancer Study Group.. <i>Journal of Clinical Oncology</i> , 2021 , 39, e20590-e20590	2.2	
98	A case of dramatic reduction in cancer-associated thrombus following initiation of pembrolizumab in patient with a poor performance status and PD-L1 lung adenocarcinoma harboring CCDC6-RET fusion gene and NF1/TP53 mutations. <i>Lung Cancer</i> , 2021 , 156, 1-4	5.9	1
97	SHP2 Inhibition Enhances the Effects of Tyrosine Kinase Inhibitors in Preclinical Models of Treatment-naïve , or -altered Non-small Cell Lung Cancer. <i>Molecular Cancer Therapeutics</i> , 2021 , 20, 1653-1662	6.1	2
96	Survival of chemo-naïve patients with EGFR mutation-positive advanced non-small cell lung cancer after treatment with afatinib and bevacizumab: updates from the Okayama Lung Cancer Study Group Trial 1404. <i>Japanese Journal of Clinical Oncology</i> , 2021 , 51, 1269-1276	2.8	2
95	Triple therapy with osimertinib, bevacizumab and cetuximab in EGFR-mutant lung cancer with HIF-1/ATGF- β expression. <i>Oncology Letters</i> , 2021 , 22, 639	2.6	
94	Randomized study comparing mannitol with furosemide for the prevention of cisplatin-induced renal toxicity in non-small cell lung cancer: The OLCSG1406 trial. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2021 , 17, 101-108	1.9	5
93	Capmatinib in Japanese patients with MET exon 14 skipping-mutated or MET-amplified advanced NSCLC: GEOMETRY mono-1 study. <i>Cancer Science</i> , 2021 , 112, 1556-1566	6.9	4
92	MAPK-pathway inhibition mediates inflammatory reprogramming and sensitizes tumors to targeted activation of innate immunity sensor RIG-I. <i>Nature Communications</i> , 2021 , 12, 5505	17.4	2
91	Phase 1/2 study of alectinib in RET-rearranged previously-treated non-small cell lung cancer (ALL-RET). <i>Translational Lung Cancer Research</i> , 2021 , 10, 314-325	4.4	3
90	Pilot evaluation of a HER2 testing in non-small-cell lung cancer. <i>Journal of Clinical Pathology</i> , 2020 , 73, 353-357	3.9	8
89	Phase II, open-label, multicenter trial of crizotinib in Japanese patients with advanced non-small cell lung cancer harboring a MET gene alteration: Co-MET study. <i>Trials</i> , 2020 , 21, 298	2.8	6

88	Capmatinib in patients with high-level MET-amplified advanced non-small cell lung cancer (NSCLC): results from the phase 2 GEOMETRY mono-1 study.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 9509-9509	2.2	9
87	Therapeutic impact of mutation subtypes and concomitant STK11 mutations in KRAS-mutated non-small cell lung cancer (NSCLC): A result of nationwide genomic screening project (LC-SCRUM-Japan).. <i>Journal of Clinical Oncology</i> , 2020 , 38, 9589-9589	2.2	4
86	Large scale clinico-genomic analyses among patients with BRAF-mutated non-small cell lung cancers (NSCLC) identified by nationwide genomic screening project (LC-SCRUM-Japan).. <i>Journal of Clinical Oncology</i> , 2020 , 38, 9590-9590	2.2	2
85	Anaplastic Lymphoma Kinase Fusion: A Review of Therapeutic Drugs and Treatment Strategies. <i>Acta Medica Okayama</i> , 2020 , 74, 371-379	0.5	1
84	Detection of epidermal growth factor receptor mutations in exhaled breath condensate using droplet digital polymerase chain reaction. <i>Oncology Letters</i> , 2020 , 20, 393	2.6	1
83	Patients' preferences and perceptions of lung cancer treatment decision making: results from Okayama lung cancer study group trial 1406. <i>Acta Oncologica</i> , 2020 , 59, 324-328	3.2	0
82	Successful Re-administration of Osimertinib in Osimertinib-induced Interstitial Lung Disease with an Organizing Pneumonia Pattern: A Case Report and Literature Review. <i>Internal Medicine</i> , 2020 , 59, 823-828	1.1	5
81	Influence of age on the efficacy of immune checkpoint inhibitors in advanced cancers: a systematic review and meta-analysis. <i>Acta Oncologica</i> , 2020 , 59, 249-256	3.2	15
80	Beneficial effect of erlotinib and trastuzumab emtansine combination in lung tumors harboring EGFR mutations. <i>Biochemical and Biophysical Research Communications</i> , 2020 , 532, 341-346	3.4	2
79	Impact of HER2 expression on EGFR-TKI treatment outcomes in lung tumors harboring EGFR mutations: A HER2-CS study subset analysis. <i>Lung Cancer</i> , 2020 , 150, 83-89	5.9	2
78	Real-world outcomes of chemoradiotherapy for unresectable Stage III non-small cell lung cancer: The SOLUTION study. <i>Cancer Medicine</i> , 2020 , 9, 6597-6608	4.8	13
77	Capmatinib in Exon 14-Mutated or -Amplified Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2020 , 383, 944-957	59.2	214
76	Immune checkpoint inhibitor efficacy and safety in older non-small cell lung cancer patients. <i>Japanese Journal of Clinical Oncology</i> , 2020 , 50, 1447-1453	2.8	5
75	Efficacy of Selpercatinib in Fusion-Positive Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2020 , 383, 813-824	59.2	194
74	EGFR-TKI acquired resistance in lung cancers harboring EGFR mutations in immunocompetent C57BL/6J mice. <i>Lung Cancer</i> , 2019 , 136, 86-93	5.9	2
73	Beneficial Effect of Osimertinib Readministration in Non-small-cell Lung Cancer Harboring an Epidermal Growth Factor Receptor (EGFR) Mutation with a History of Acquired Resistance to Osimertinib. <i>Internal Medicine</i> , 2019 , 58, 1625-1627	1.1	2
72	Programmed cell death-ligand 1 expression and efficacy of cisplatin-based chemotherapy in lung cancer: A sub-analysis of data from the two Okayama Lung Cancer Study Group prospective feasibility studies. <i>Respiratory Investigation</i> , 2019 , 57, 460-465	3.4	2
71	A Prospective Cohort Study to Define the Clinical Features and Outcome of Lung Cancers Harboring HER2 Aberration in Japan (HER2-CS STUDY). <i>Chest</i> , 2019 , 156, 357-366	5.3	16

70	The effect and safety of immune checkpoint inhibitor rechallenge in non-small cell lung cancer. <i>Japanese Journal of Clinical Oncology</i> , 2019 , 49, 762-765	2.8	30
69	Chemoradiotherapy for locally advanced lung cancer patients with interstitial lung abnormalities. <i>Japanese Journal of Clinical Oncology</i> , 2019 , 49, 458-464	2.8	9
68	A phase I/II trial of weekly nab-paclitaxel for pretreated non-small-cell lung cancer patients without epidermal growth factor receptor mutations and anaplastic lymphoma kinase rearrangement. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2019 , 15, 250-256	1.9	2
67	Re-administration of osimertinib in osimertinib-acquired resistant non-small-cell lung cancer. <i>Lung Cancer</i> , 2019 , 132, 54-58	5.9	9
66	A Long-term Response to Nivolumab in a Case of PD-L1-negative Lung Adenocarcinoma with an EGFR Mutation and Surrounding PD-L1-positive Tumor-associated Macrophages. <i>Internal Medicine</i> , 2019 , 58, 3033-3037	1.1	5
65	Long-term spontaneous remission with active surveillance in IgG4-related pleuritis: A case report and literature review. <i>Respiratory Medicine Case Reports</i> , 2019 , 28, 100938	1.2	3
64	A case of axillary lymphadenitis caused by in an immunocompetent patient. <i>Respiratory Medicine Case Reports</i> , 2019 , 28, 100947	1.2	
63	Rapid Acquisition of Alectinib Resistance in ALK-Positive Lung Cancer With High Tumor Mutation Burden. <i>Journal of Thoracic Oncology</i> , 2019 , 14, 2009-2018	8.9	12
62	Abstract 2131: Significant combination benefit of anti-VEGFR antibody and oncogene-targeted agents in EGFR or ALK mutant NSCLC cells 2019 ,		3
61	Impact of HER2 aberrations on EGFR-TKI treatment outcomes in lung tumors harboring EGFR mutations: A HER2-CS STUDY subset analysis.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 9056-9056	2.2	1
60	Randomized phase II study comparing mannitol with furosemide for the prevention of cisplatin-induced renal toxicity in advanced non-small cell lung cancer: The OLCSG1406 trial.. <i>Journal of Clinical Oncology</i> , 2019 , 37, e23105-e23105	2.2	1
59	Tumor microenvironment affecting the effect of immuno-checkpoint inhibitors. <i>Okayama Igakkai Zasshi</i> , 2019 , 131, 51-53	0	
58	Second primary cancer in survivors of locally advanced non-small cell lung cancer treated with concurrent chemoradiation followed by surgery. <i>Japanese Journal of Clinical Oncology</i> , 2018 , 48, 287-290	2.8	3
57	MET or NRAS amplification is an acquired resistance mechanism to the third-generation EGFR inhibitor naquotinib. <i>Scientific Reports</i> , 2018 , 8, 1955	4.9	26
56	A Phase II Study of Trastuzumab Emtansine in HER2-Positive Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2018 , 13, 273-279	8.9	74
55	Osimertinib Depletes EGFR T790M in the Spinal Fluid of Patients with Carcinomatous Meningitis of Lung Adenocarcinoma Harboring De Novo EGFR T790M. <i>Journal of Thoracic Oncology</i> , 2018 , 13, e140-e142	8.9	4
54	Contribution of nationwide genome screening in Japan (LC-SCRUM-Japan) to the development of precision medicine for non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 9085-9085	2.2	4
53	The effect and safety of an immune checkpoint inhibitor rechallenge in non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2018 , 36, e21147-e21147	2.2	2

52	Clinical significance of repeat rebiopsy in detecting the EGFR T790M secondary mutation in patients with non-small cell lung cancer. <i>Oncotarget</i> , 2018 , 9, 29525-29531	3.3	25
51	Immune checkpoint inhibitor efficacy and safety in elderly non-small cell lung cancer patients.. <i>Journal of Clinical Oncology</i> , 2018 , 36, e21034-e21034	2.2	
50	A phase I trial of afatinib and bevacizumab in chemo-naïve patients with advanced non-small-cell lung cancer harboring EGFR mutations: Okayama Lung Cancer Study Group Trial 1404. <i>Lung Cancer</i> , 2018 , 115, 103-108	5.9	19
49	Potential influence of interleukin-6 on the therapeutic effect of gefitinib in patients with advanced non-small cell lung cancer harbouring EGFR mutations. <i>Biochemical and Biophysical Research Communications</i> , 2018 , 495, 360-367	3.4	14
48	Combined effect of cabozantinib and gefitinib in crizotinib-resistant lung tumors harboring ROS1 fusions. <i>Cancer Science</i> , 2018 , 109, 3149-3158	6.9	12
47	Randomized Phase II Study Comparing Mannitol with Furosemide for the Prevention of Renal Toxicity Induced by Cisplatin-based Chemotherapy with Short-term Low-volume Hydration in Advanced Non-small Cell Lung Cancer: The OLCSG1406 Study Protocol. <i>Acta Medica Okayama</i> , 2018 , 72, 318-323	0.5	4
46	Discomfort during bronchoscopy performed after endobronchial intubation with fentanyl and midazolam: a prospective study. <i>Japanese Journal of Clinical Oncology</i> , 2017 , 47, 434-437	2.8	3
45	Optimal method for quantitative detection of plasma EGFR T790M mutation using droplet digital PCR system. <i>Oncology Reports</i> , 2017 , 37, 3100-3106	3.5	11
44	Triplet therapy with afatinib, cetuximab, and bevacizumab induces deep remission in lung cancer cells harboring EGFR T790M <i>in vivo</i> . <i>Molecular Oncology</i> , 2017 , 11, 670-681	7.9	9
43	A phase II trial of carboplatin plus S-1 for elderly patients with advanced non-small-cell lung cancer with wild-type epidermal growth factor receptor: The Okayama Lung Cancer Study Group Trial 1202. <i>Lung Cancer</i> , 2017 , 112, 188-194	5.9	4
42	Trastuzumab Emtansine in HER2+ Recurrent Metastatic Non-Small-Cell Lung Cancer: Study Protocol. <i>Clinical Lung Cancer</i> , 2017 , 18, 92-95	4.9	19
41	The effect of nivolumab treatment for central nervous system metastases in non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2017 , 35, e20601-e20601	2.2	12
40	Chemoradiotherapy (CRT) for locally-advanced (LA) lung cancer patients with interstitial lung abnormalities (ILA).. <i>Journal of Clinical Oncology</i> , 2017 , 35, e20057-e20057	2.2	
39	Contribution to the development of precision medicine and clinical utility of nationwide lung cancer genomic screening in Japan (LC-SCRUM-Japan).. <i>Journal of Clinical Oncology</i> , 2017 , 35, e20659-e20659	2.2	59
38	Protocol Design for the Bench to Bed Trial in Alectinib-Refractory Non-Small-Cell Lung Cancer Patients Harboring the EML4-ALK Fusion Gene (ALRIGHT/OLCSG1405). <i>Clinical Lung Cancer</i> , 2016 , 17, 602-605	4.9	10
37	Endobronchial ultrasound-guided transbronchial needle aspiration of hilar and mediastinal lymph nodes detected on 18F-fluorodeoxyglucose positron emission tomography/computed tomography. <i>Japanese Journal of Clinical Oncology</i> , 2016 , 46, 529-33	2.8	1
36	Non-Small Cell Lung Cancer Cells Acquire Resistance to the ALK Inhibitor Alectinib by Activating Alternative Receptor Tyrosine Kinases. <i>Cancer Research</i> , 2016 , 76, 1506-16	10.1	91
35	Development of a nationwide genomic screening network for squamous cell lung cancer in Japan (LC-SCRUM-Japan).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 9097-9097	2.2	

34	Second primary cancer in survivors of locally advanced NSCLC treated with concurrent chemoradiation followed by surgery.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 10100-10100	2.2	
33	Association with consolidation chemotherapy after concurrent chemoradiotherapy followed by surgery and the disease free survival in patients with stage III non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2016 , 34, e20053-e20053	2.2	
32	Development of nationwide genomic screening project (LC-SCRUM-Japan) contributing to the establishment of precision medicine in Japan.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 9089-9089	2.2	
31	Efficacy of multimodal treatment for leptomeningeal metastases in a lung cancer harboring an EGFR mutation. <i>OncoTargets and Therapy</i> , 2016 , 9, 1753-8	4.4	4
30	Safety and discomfort during bronchoscopy performed under sedation with fentanyl and midazolam: a prospective study. <i>Japanese Journal of Clinical Oncology</i> , 2016 , 46, 871-4	2.8	7
29	Potential influence of being overweight on the development of hepatic dysfunction in Japanese patients with EGFR-mutated non-small cell lung cancer undergoing gefitinib monotherapy: the Okayama Lung Cancer Study Group experience. <i>Cancer Chemotherapy and Pharmacology</i> , 2016 , 78, 941-947	3.5	5
28	Effect of Vandetanib on Lung Tumorigenesis in Transgenic Mice Carrying an Activating Egfr Gene Mutation. <i>Acta Medica Okayama</i> , 2016 , 70, 243-53	0.5	
27	Downregulation of TBXAS1 in an iron-induced malignant mesothelioma model. <i>Cancer Science</i> , 2015 , 106, 1296-302	6.9	10
26	Magnitude of the benefit of progression-free survival as a potential surrogate marker in phase 3 trials assessing targeted agents in molecularly selected patients with advanced non-small cell lung cancer: systematic review. <i>PLoS ONE</i> , 2015 , 10, e0121211	3.7	14
25	Endobronchial ultrasound-guided transbronchial biopsy with or without a guide sheath for diagnosis of lung cancer. <i>Respiratory Investigation</i> , 2015 , 53, 93-7	3.4	9
24	NF- κ B drives acquired resistance to a novel mutant-selective EGFR inhibitor. <i>Oncotarget</i> , 2015 , 6, 42717-33	3.3	27
23	A prospective cohort study to define the clinical and pathological features of lung cancers harboring HER2 gene aberrations (the HER2-CS Study) and a phase II study of trastuzumab emtansine (recombinant) in patients with HER2-positive non-small cell lung cancer who recurred, progressed, or had no response to first-line chemotherapy	0	
22	Everolimus prolonged survival in transgenic mice with EGFR-driven lung tumors. <i>Experimental Cell Research</i> , 2014 , 326, 201-9	4.2	5
21	Time trend in the survival advantage in phase III trials investigating molecular-targeted agents for advanced non-small cell lung cancer (NSCLC) during the past decade.. <i>Journal of Clinical Oncology</i> , 2014 , 32, e19084-e19084	2.2	
20	Vandetanib is effective in EGFR-mutant lung cancer cells with PTEN deficiency. <i>Experimental Cell Research</i> , 2013 , 319, 417-23	4.2	20
19	Characteristics of lung cancers harboring NRAS mutations. <i>Clinical Cancer Research</i> , 2013 , 19, 2584-91	12.9	100
18	Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease. <i>Journal of Clinical Oncology</i> , 2013 , 31, 1070-80	2.2	362
17	Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC. <i>Cancer Discovery</i> , 2013 , 3, 1404-15	24.4	493

16	Next-generation sequencing of paired tyrosine kinase inhibitor-sensitive and -resistant EGFR mutant lung cancer cell lines identifies spectrum of DNA changes associated with drug resistance. <i>Genome Research</i> , 2013 , 23, 1434-45	9.7	41
15	Lower gefitinib dose led to earlier resistance acquisition before emergence of T790M mutation in epidermal growth factor receptor-mutated lung cancer model. <i>Cancer Science</i> , 2013 , 104, 1440-6	6.9	24
14	Abstract 2101A: CNX-2006, a novel irreversible epidermal growth factor receptor (EGFR) inhibitor, selectively inhibits EGFR T790M and fails to induce T790M-mediated resistance in vitro. 2013 ,		6
13	JAK2-related pathway induces acquired erlotinib resistance in lung cancer cells harboring an epidermal growth factor receptor-activating mutation. <i>Cancer Science</i> , 2012 , 103, 1795-802	6.9	38
12	HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFR T790M mutation. <i>Cancer Discovery</i> , 2012 , 2, 922-33	24.4	528
11	STAT3 expression in activating EGFR-driven adenocarcinoma of the lung. <i>Lung Cancer</i> , 2012 , 75, 24-9	5.9	16
10	Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012 , 109, E2127-33	11.5	366
9	Ruptured littoral cell angiosarcoma causing hemoperitoneum. <i>Internal Medicine</i> , 2012 , 51, 337-8	1.1	4
8	Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling. <i>Science Translational Medicine</i> , 2011 , 3, 90ra59	17.5	383
7	A new target for therapy in squamous cell carcinoma of the lung. <i>Cancer Discovery</i> , 2011 , 1, 23-4	24.4	10
6	Effects of vandetanib on lung adenocarcinoma cells harboring epidermal growth factor receptor T790M mutation in vivo. <i>Cancer Research</i> , 2009 , 69, 5091-8	10.1	52
5	Chemopreventive effects of gefitinib on nonsmoking-related lung tumorigenesis in activating epidermal growth factor receptor transgenic mice. <i>Cancer Research</i> , 2009 , 69, 7088-95	10.1	16
4	Effect of gefitinib on N-nitrosamine-4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone induced lung tumorigenesis in A/J mice. <i>Lung Cancer</i> , 2009 , 65, 284-9	5.9	9
3	Induction of lung adenocarcinoma in transgenic mice expressing activated EGFR driven by the SP-C promoter. <i>Cancer Science</i> , 2008 , 99, 1747-53	6.9	19
2	Radiation necrosis mimicking progressive brain metastasis in a patient with non-small cell lung cancer. <i>Journal of Thoracic Oncology</i> , 2007 , 2, 762-3	8.9	2
1	Double mutation and gene copy number of EGFR in gefitinib refractory non-small-cell lung cancer. <i>Lung Cancer</i> , 2006 , 53, 117-21	5.9	53